Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals has announced the safety and efficacy results of randomized, vehicle-controlled, double-blinded study which evaluated Ampion in nasal inflammation treatment.
Subscribe to our email newsletter
Ampion is a non-steroidal anti inflammatory drug indicated for treatment in the homeostasis of inflammation.
During the course of the study, twenty patients were randomized to receive either intranasal Ampion, or saline, twice a day during a 10 day double-blind period which followed a one week washout period.
The subjects reported reflective total nasal symptom scores (rTNSS) as well as instantaneous total nasal symptom scores (iTNSS) every 12 hours.
The trial demonstrated an improvement in rTNSS in the intranasal Ampion group over the saline group.